1. In Vivo
  2. >>Archive

Practical Dealmaking in Discovery: The Structural Biology Case

Discovery dealmaking is by no means dead-but it's certainly been practicalized. In the last few months, one good example of a still interesting discovery area--high-throughput structural biology--has seen a flurry of dealmaking. But it's not yet frequent or rich enough to justify the venture valuations originally applied to them. And the deals themselves reflect the results-oriented conservatism of Big Pharma buyers.

Discovery dealmaking is by no means dead—but it's certainly been practicalized. The deals are also a lot less costly for technology buyers. "These deals take a lot more work than they used to," says Michael Grey, chief business officer at Structural GenomiX Inc. (SGX) "No one's selling technology on promise anymore. Technology purchasing decisions are being made on the basis of data—that the technology can do what's claimed for it and deliver benefit."

He should know. In the last few months, his industry segment--high-throughput structural biology--has seen a flurry of dealmaking. But it's not yet frequent or rich enough to justify the venture...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

 
• By David Wild

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.

Execs On The Move: April 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.